EXAS vs. HUM: A Head-to-Head Stock Comparison
Updated onHere’s a clear look at EXAS and HUM, comparing key factors like historical performance, profitability, financial strength, growth, dividend, and valuation.
Company Profile
| Symbol | EXAS | HUM |
|---|---|---|
| Company Name | Exact Sciences Corporation | Humana Inc. |
| Country | United States | United States |
| GICS Sector | Health Care | Health Care |
| GICS Industry | Biotechnology | Health Care Providers & Services |
| Market Capitalization | 8.99 billion USD | 36.02 billion USD |
| Exchange | NasdaqCM | NYSE |
| Listing Date | February 1, 2001 | December 31, 1981 |
| Security Type | Common Stock | Common Stock |
Historical Performance
This chart compares the performance of EXAS and HUM by tracking the growth of an initial $10,000 investment in each. Use the tabs to select the desired time period. Data is adjusted for dividends and splits.
Historical Performance at a Glance
| Symbol | EXAS | HUM |
|---|---|---|
| 5-Day Price Return | 5.28% | 4.29% |
| 13-Week Price Return | -16.56% | 21.87% |
| 26-Week Price Return | -4.35% | 16.43% |
| 52-Week Price Return | -20.46% | -16.47% |
| Month-to-Date Return | 1.11% | 19.87% |
| Year-to-Date Return | -15.52% | 18.05% |
| 10-Day Avg. Volume | 3.49M | 1.54M |
| 3-Month Avg. Volume | 3.10M | 1.78M |
| 3-Month Volatility | 38.63% | 41.05% |
| Beta | 1.22 | 0.47 |
Profitability
Return on Equity (TTM)
EXAS
-38.37%
Biotechnology Industry
- Max
- 77.14%
- Q3
- 10.76%
- Median
- -20.08%
- Q1
- -42.71%
- Min
- -119.20%
EXAS has a negative Return on Equity of -38.37%. This indicates the company is generating a loss for its shareholders, which can be a result of unprofitability or negative shareholder equity and is often a sign of financial distress.
HUM
9.02%
Health Care Providers & Services Industry
- Max
- 26.03%
- Q3
- 13.74%
- Median
- 8.26%
- Q1
- 4.13%
- Min
- -3.62%
HUM’s Return on Equity of 9.02% is on par with the norm for the Health Care Providers & Services industry, indicating its profitability relative to shareholder equity is typical for the sector.
Net Profit Margin (TTM)
EXAS
-34.19%
Biotechnology Industry
- Max
- 59.44%
- Q3
- 16.21%
- Median
- -11.49%
- Q1
- -167.42%
- Min
- -409.07%
EXAS has a negative Net Profit Margin of -34.19%, indicating the company is operating at a net loss as its expenses exceeded its revenues.
HUM
1.28%
Health Care Providers & Services Industry
- Max
- 12.40%
- Q3
- 5.93%
- Median
- 1.96%
- Q1
- 0.93%
- Min
- -6.10%
HUM’s Net Profit Margin of 1.28% is aligned with the median group of its peers in the Health Care Providers & Services industry. This indicates its ability to convert revenue into profit is typical for the sector.
Operating Profit Margin (TTM)
EXAS
-34.49%
Biotechnology Industry
- Max
- 60.62%
- Q3
- 20.76%
- Median
- -12.41%
- Q1
- -181.14%
- Min
- -482.02%
EXAS has a negative Operating Profit Margin of -34.49%. This signifies the company is unprofitable at the operational level, as its core business expenses exceed its revenue.
HUM
2.68%
Health Care Providers & Services Industry
- Max
- 19.05%
- Q3
- 10.21%
- Median
- 4.22%
- Q1
- 1.98%
- Min
- -4.27%
HUM’s Operating Profit Margin of 2.68% is around the midpoint for the Health Care Providers & Services industry, indicating that its efficiency in managing core business operations is typical for the sector.
Profitability at a Glance
| Symbol | EXAS | HUM |
|---|---|---|
| Return on Equity (TTM) | -38.37% | 9.02% |
| Return on Assets (TTM) | -16.63% | 3.19% |
| Net Profit Margin (TTM) | -34.19% | 1.28% |
| Operating Profit Margin (TTM) | -34.49% | 2.68% |
| Gross Profit Margin (TTM) | 68.19% | -- |
Financial Strength
Current Ratio (MRQ)
EXAS
2.89
Biotechnology Industry
- Max
- 19.31
- Q3
- 9.38
- Median
- 4.54
- Q1
- 2.45
- Min
- 0.76
EXAS’s Current Ratio of 2.89 aligns with the median group of the Biotechnology industry, indicating that its short-term liquidity is in line with its sector peers.
HUM
0.01
Health Care Providers & Services Industry
- Max
- 2.01
- Q3
- 1.49
- Median
- 1.30
- Q1
- 0.94
- Min
- 0.17
HUM’s Current Ratio of 0.01 is notably low, falling beneath the typical range for the Health Care Providers & Services industry. This suggests a heightened liquidity risk and could indicate potential challenges in meeting its short-term obligations.
Debt-to-Equity Ratio (MRQ)
EXAS
0.95
Biotechnology Industry
- Max
- 1.35
- Q3
- 0.64
- Median
- 0.09
- Q1
- 0.00
- Min
- 0.00
EXAS’s leverage is in the upper quartile of the Biotechnology industry, with a Debt-to-Equity Ratio of 0.95. While this approach can boost equity growth, it also exposes the company to greater financial vulnerability.
HUM
0.69
Health Care Providers & Services Industry
- Max
- 2.17
- Q3
- 1.18
- Median
- 0.74
- Q1
- 0.45
- Min
- 0.00
HUM’s Debt-to-Equity Ratio of 0.69 is typical for the Health Care Providers & Services industry, indicating its use of leverage is in line with the sector norm. This suggests a balanced approach to its capital structure.
Interest Coverage Ratio (TTM)
EXAS
-15.18
Biotechnology Industry
- Max
- 72.37
- Q3
- 1.91
- Median
- -7.81
- Q1
- -63.90
- Min
- -153.80
EXAS has a negative Interest Coverage Ratio of -15.18. This indicates that its earnings were insufficient to cover even its operational costs, let alone its interest payments, signaling significant financial distress.
HUM
3.61
Health Care Providers & Services Industry
- Max
- 14.47
- Q3
- 7.15
- Median
- 5.45
- Q1
- 2.04
- Min
- -4.44
HUM’s Interest Coverage Ratio of 3.61 is positioned comfortably within the norm for the Health Care Providers & Services industry, indicating a standard and healthy capacity to cover its interest payments.
Financial Strength at a Glance
| Symbol | EXAS | HUM |
|---|---|---|
| Current Ratio (MRQ) | 2.89 | 0.01 |
| Quick Ratio (MRQ) | 2.32 | 0.01 |
| Debt-to-Equity Ratio (MRQ) | 0.95 | 0.69 |
| Interest Coverage Ratio (TTM) | -15.18 | 3.61 |
Growth
Revenue Growth
EPS Growth
Dividend
Dividend Yield (TTM)
EXAS
0.00%
Biotechnology Industry
- Max
- 0.00%
- Q3
- 0.00%
- Median
- 0.00%
- Q1
- 0.00%
- Min
- 0.00%
EXAS currently does not pay a dividend, resulting in a yield of 0%. This is a common strategy for growth-focused companies that prioritize reinvesting earnings, though it may be less typical in mature, income-oriented sectors.
HUM
1.25%
Health Care Providers & Services Industry
- Max
- 5.38%
- Q3
- 2.22%
- Median
- 0.55%
- Q1
- 0.00%
- Min
- 0.00%
HUM’s Dividend Yield of 1.25% is consistent with its peers in the Health Care Providers & Services industry, providing a dividend return that is standard for its sector.
Dividend Payout Ratio (TTM)
EXAS
0.00%
Biotechnology Industry
- Max
- 0.00%
- Q3
- 0.00%
- Median
- 0.00%
- Q1
- 0.00%
- Min
- 0.00%
EXAS has a Dividend Payout Ratio of 0%, indicating it does not currently pay a dividend. This is a common strategy for growth-oriented companies that reinvest all profits back into the business.
HUM
14.15%
Health Care Providers & Services Industry
- Max
- 186.69%
- Q3
- 74.82%
- Median
- 26.76%
- Q1
- 0.00%
- Min
- 0.00%
HUM’s Dividend Payout Ratio of 14.15% is within the typical range for the Health Care Providers & Services industry, suggesting a balanced approach between shareholder payouts and company reinvestment.
Dividend at a Glance
| Symbol | EXAS | HUM |
|---|---|---|
| Dividend Yield (TTM) | 0.00% | 1.25% |
| Dividend Payout Ratio (TTM) | 0.00% | 14.15% |
Valuation
Price-to-Earnings Ratio (TTM)
EXAS
--
Biotechnology Industry
- Max
- 60.14
- Q3
- 38.17
- Median
- 29.01
- Q1
- 15.12
- Min
- 0.00
P/E Ratio data for EXAS is currently unavailable.
HUM
21.85
Health Care Providers & Services Industry
- Max
- 55.89
- Q3
- 30.85
- Median
- 21.17
- Q1
- 12.63
- Min
- 0.00
HUM’s P/E Ratio of 21.85 is within the middle range for the Health Care Providers & Services industry. This suggests its valuation is in line with the sector average, representing neither a significant premium nor a discount compared to its peers.
Price-to-Sales Ratio (TTM)
EXAS
2.92
Biotechnology Industry
- Max
- 76.98
- Q3
- 36.53
- Median
- 9.49
- Q1
- 4.49
- Min
- 0.00
In the lower quartile for the Biotechnology industry, EXAS’s P/S Ratio of 2.92 indicates its revenue is valued more conservatively than most of its peers. This could present a compelling opportunity if the market has overlooked its sales-generating capabilities.
HUM
0.28
Health Care Providers & Services Industry
- Max
- 3.10
- Q3
- 1.74
- Median
- 0.67
- Q1
- 0.24
- Min
- 0.00
HUM’s P/S Ratio of 0.28 aligns with the market consensus for the Health Care Providers & Services industry. This suggests its valuation, based on sales, is seen as standard and is on par with its competitors.
Price-to-Book Ratio (MRQ)
EXAS
4.06
Biotechnology Industry
- Max
- 20.53
- Q3
- 9.76
- Median
- 4.77
- Q1
- 2.49
- Min
- 0.59
EXAS’s P/B Ratio of 4.06 is within the conventional range for the Biotechnology industry. This shows a balanced market view, where the stock’s price is neither at a significant premium nor a discount to the book value of its peers.
HUM
1.62
Health Care Providers & Services Industry
- Max
- 7.61
- Q3
- 4.32
- Median
- 2.53
- Q1
- 1.14
- Min
- 0.77
HUM’s P/B Ratio of 1.62 is within the conventional range for the Health Care Providers & Services industry. This shows a balanced market view, where the stock’s price is neither at a significant premium nor a discount to the book value of its peers.
Valuation at a Glance
| Symbol | EXAS | HUM |
|---|---|---|
| Price-to-Earnings Ratio (TTM) | -- | 21.85 |
| Price-to-Sales Ratio (TTM) | 2.92 | 0.28 |
| Price-to-Book Ratio (MRQ) | 4.06 | 1.62 |
| Price-to-Free Cash Flow Ratio (TTM) | 68.70 | 11.03 |